Resumen
Gastroesophageal cancer is a devastating disease with dismal survival even in localized settings. Novel therapeutic regimen are underway to improve patient management and outcome. This review aims to demonstrate the advances of immunotherapy and targeted therapies in treatment of localized gastric, gastroesophageal junction and esophageal tumors and gives a short summary on promising ongoing clinical trials.